116842-80-9

Basic information

• Product Name: (S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-phenyl-2-propenamide
• CAS NO: 116842-80-9
• Molecular Weight: 395.461
• Mol File: 116842-80-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-phenyl-2-propenamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-phenyl-2-propenamide(116842-80-9)
• EPA Substance Registry System: (S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-phenyl-2-propenamide(116842-80-9)

Safety Data

• Hazardous Substances Data: 116842-80-9(Hazardous Substances Data)

Upstream product

• 103343-66-4 (S)-3-amino-1-methyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 102-92-1 Cinnamoyl chloride 

Relevant articles and documents

Benzodiazepine analogs for treating panic syndrome and for directly inducing analgesia

From EXEMP_CLAIMS : 1. A pharmaceutical composition useful in treatment of panic disorder or other neurological disorders involving anxiety, comprising an effective amount of a CCK and/or gastrin antagonist compound of the formula: wherein: R1 is H, C1-6 linear or branched alkyl, X12-cycloalkyl, -X12COOR6, R2 is substituted or unsubstituted phenyl (wherein the substituents may be 1 or 2 of halo, loweralkyl, carboxyl, nitro or -CF3); -X12COOR6; 2-, 3-, 4-pyridyl; R4 and R5 are independently R6 or in combination with the N of the NR4R5 group form an unsubstituted or mono- or disubstituted, saturated or unsaturated, 4-7 membered heterocyclic ring, or benzofused 4-7 membered heterocyclic ring wherein said heterocyclic ring or said benzofused heterocyclic ring may contain a second heteroatom selected from 0 and NCH3 and the substituent(s) is/are independently selected from C1-4 alkyl; R6 is H, C1-6 straight or branched-chain alkyl or cycloalkyl; R7 is α- or β-naphthyl, substituted or unsubstituted phenyl (wherein the substitutents may be 1 to 2 of halo, -NO2, -OH,-NR4R5, loweralkyl, CF3, CN, COOR6, X12COOR6, X12OR6, or loweralkoxy), 2-, 3-, 4-pyridyl, R8 is H, loweralkyl, cycloloweralkyl, X12COOR6; X1 is H, -NO2, CF3, loweralkyl or halo; X2 and X3 are independently H, -NO2, OH, halo, loweralkyl, or loweralkoxy, X12COOR6, COOR6, or OX12COOR6; X4 is O, or NR8; X7 is O; X12 is C1-5 linear or branched chain alkyl, or the pharmaceutically acceptable salt thereof.

Methods for Drug Discovery: Development of Potent, Selective, Orally Effecive Cholecystokinin Antagonists

3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines, antagonists of the peptide hormone cholecystokinin (CCK), are described.Developed by reasoned modification of the known anxiolytic benzodiazepines, these compounds provide highly potent, orally effective ligands selective for peripheral (CCK-A) receptors, with binding affinities approaching or equaling that of the natural ligand CCK-8.The distinction between CCK-A receptors on the one hand and CNS (CCK-B), gastrin, and central benzodiazepine receptors on the other is demonstrated by using the structure-activity profiles of the new compounds.Details of the binding of these agents to CCK-A receptors are examined, and the method of development of these compounds is discussed in terms of its relevance to the general problem of drug discovery.